STING MARK Universal Fiducial Marker System

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jul 15, 2022

Keywords

ClinConnect Summary

The STING MARK trial is studying a new device called the STING-MARK Universal Fiducial Marker System, designed to help doctors more accurately locate tumors in patients with cancer. Current methods for marking tumor locations are often not very reliable, which can make treatment more difficult. The STING-MARK device is unique because it can be easily attached to a needle that delivers it directly to the tumor, allowing for better guidance during treatments like radiation therapy. This trial aims to test how well the device works in different types of organ samples to ensure it is safe and effective.

To participate in this trial, you should be between the ages of 65 and 74 and be undergoing surgery for a solid organ (like the liver or kidney) or receiving a solid organ transplant. There are no specific exclusions based on other health conditions, so many patients may be eligible. If you join the study, you can expect to have the STING-MARK device used during your procedure, and researchers will observe how well it performs. Your involvement will help improve future cancer treatments and may also provide valuable information for doctors and patients alike.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing surgical resection of solid organs
• • Recipients of solid organ transplantation
• Exclusion Criteria:
• • None